CoQ10 supplementation rescues nephrotic syndrome through normalization of H2S oxidation pathway

Biochim Biophys Acta Mol Basis Dis. 2018 Nov;1864(11):3708-3722. doi: 10.1016/j.bbadis.2018.09.002. Epub 2018 Sep 6.

Abstract

Nephrotic syndrome (NS), a frequent chronic kidney disease in children and young adults, is the most common phenotype associated with primary coenzyme Q10 (CoQ10) deficiency and is very responsive to CoQ10 supplementation, although the pathomechanism is not clear. Here, using a mouse model of CoQ deficiency-associated NS, we show that long-term oral CoQ10 supplementation prevents kidney failure by rescuing defects of sulfides oxidation and ameliorating oxidative stress, despite only incomplete normalization of kidney CoQ levels and lack of rescue of CoQ-dependent respiratory enzymes activities. Liver and kidney lipidomics, and urine metabolomics analyses, did not show CoQ metabolites. To further demonstrate that sulfides metabolism defects cause oxidative stress in CoQ deficiency, we show that silencing of sulfide quinone oxido-reductase (SQOR) in wild-type HeLa cells leads to similar increases of reactive oxygen species (ROS) observed in HeLa cells depleted of the CoQ biosynthesis regulatory protein COQ8A. While CoQ10 supplementation of COQ8A depleted cells decreases ROS and increases SQOR protein levels, knock-down of SQOR prevents CoQ10 antioxidant effects. We conclude that kidney failure in CoQ deficiency-associated NS is caused by oxidative stress mediated by impaired sulfides oxidation and propose that CoQ supplementation does not significantly increase the kidney pool of CoQ bound to the respiratory supercomplexes, but rather enhances the free pool of CoQ, which stabilizes SQOR protein levels rescuing oxidative stress.

Keywords: CoQ deficiency; Coenzyme Q(10); Mitochondria; Oxidative stress; Sulfides.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Alkyl and Aryl Transferases / genetics
  • Animals
  • Antioxidants / pharmacology*
  • Antioxidants / therapeutic use
  • Ataxia / complications
  • Ataxia / drug therapy*
  • Ataxia / metabolism
  • Disease Models, Animal
  • HeLa Cells
  • Humans
  • Hydrogen Sulfide / metabolism*
  • Kidney / metabolism
  • Kidney / pathology
  • Metabolic Networks and Pathways / drug effects
  • Mice
  • Mice, Transgenic
  • Mitochondria / drug effects
  • Mitochondria / metabolism
  • Mitochondrial Diseases / complications
  • Mitochondrial Diseases / drug therapy*
  • Mitochondrial Diseases / metabolism
  • Muscle Weakness / complications
  • Muscle Weakness / drug therapy*
  • Muscle Weakness / metabolism
  • Nephrotic Syndrome / drug therapy*
  • Nephrotic Syndrome / etiology
  • Nephrotic Syndrome / metabolism
  • Nephrotic Syndrome / pathology
  • Oxidation-Reduction / drug effects
  • Oxidative Stress / drug effects
  • Oxidoreductases Acting on Sulfur Group Donors / genetics
  • Oxidoreductases Acting on Sulfur Group Donors / metabolism
  • Reactive Oxygen Species / metabolism
  • Ubiquinone / analogs & derivatives*
  • Ubiquinone / deficiency*
  • Ubiquinone / metabolism
  • Ubiquinone / pharmacology
  • Ubiquinone / therapeutic use

Substances

  • Antioxidants
  • Reactive Oxygen Species
  • Ubiquinone
  • Oxidoreductases Acting on Sulfur Group Donors
  • SQOR protein, human
  • Alkyl and Aryl Transferases
  • prenyl diphosphate synthase subunit 2, mouse
  • coenzyme Q10
  • idebenone
  • Hydrogen Sulfide

Supplementary concepts

  • Coenzyme Q10 Deficiency